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To mount an effective type 1 immune response, type 1 T helper (Th1) cells must produce 
inflammatory cytokines and simultaneously suppress the expression of antiinflammatory 
cytokines. How these two processes are coordinately regulated at the molecular level is still 
unclear. In this paper, we show that the proto-oncogene E26 transformation–specific-1 
(Ets-1) is necessary for T-bet to promote interferon-
 
 
 
 production and that Ets-1 is essential 
for mounting effective Th1 inflammatory responses in vivo. In addition, Ets-1–deficient Th1 
cells also produce a very high level of interleukin 10. Thus, Ets-1 plays a crucial and unique 
role in the reciprocal regulation of inflammatory and antiinflammatory Th responses.
 
Th cells play a pivotal role in adaptive immu-
nity. Type 1 Th (Th1) cells produce mainly
IL-2 and IFN-
 
 
 
 and direct immune responses
against intracellular pathogens. Type 2 Th (Th2)
cells produce IL-4, IL-5, and IL-13 and are
important for elimination of certain extracellular
pathogens and parasites (1–3). However, Th
cells are also capable of producing antiinflam-
matory cytokines, such as IL-10 and TGF-
 
 
 
,
thereby attenuating Th immune responses (4,
5). Thus, both the production of inflammatory
cytokines and the suppression of antiinflamma-
tory cytokines must be coordinately regulated
to generate effective Th immune responses.
The molecular events controlling the differ-
entiation and function of Th cells have re-
cently been characterized. The differentiation
of common Th precursor cells into Th1 or
Th2 cells is determined by the cytokine milieu
and two critical transcription factors, T-bet
and GATA-3 (6, 7). IL-4/STAT6 signals induce
the expression of GATA-3, a Th2 cell–specific
transcription factor, which promotes the dif-
ferentiation of Th2 cells (8–10). IFN-
 
 
 
 induces
T-bet via STAT1 phosphorylation (11, 12).
T-bet is a very potent transactivator of the
IFN-
 
 
 
 gene, thereby reinforcing the expression
of IFN-
 
 
 
 (7, 13). In addition to T-bet, stable
Th1 commitment also requires signals deliv-
ered by IL-12 via STAT4 (13, 14). However,
naive CD4 cells do not possess a functional IL-12
receptor (15). T-bet is also responsible for the
up-regulation of the IL-12 receptor 
 
 
 
2 (IL-
12R
 
 
 
2) chain (11), enabling IL-12 signaling
and terminal Th1 differentiation. Thus, T-bet
has been regarded as the “master switch” of
Th1 cells. Yet, despite the fact that forced ex-
pression of T-bet is sufficient to convert differ-
entiating Th2 cells into Th1 cells, it is unclear
whether T-bet can act alone or requires other
transcription factors to drive the differentiation
of Th1 cells and simultaneously suppress the
expression of antiinflammatory cytokines.
Ets-1 (E26 transformation–specific-1) is the
prototype of the ETS family of transcription
factors, which are characterized by a conserved
ETS domain that is capable of binding to DNA
sequences containing a core GGAA/T motif
(16, 17). Studies on Ets-1–deficient (Ets-1
 
   
 
)
mice have demonstrated that Ets-1 is important
for T cell development, proliferation, and
survival (18–20). In addition, Ets-1 has been
shown to regulate several cytokine gene pro-
moters. Overexpression of Ets-1 suppressed the
activity of an IL-2 promoter and transactivated
IL-5 and GM-CSF promoters in vitro, suggest-
ing that Ets-1 might also modulate the effector
function of Th cells (21–23). Despite these ob-
servations, the regulatory roles of Ets-1 in Th
immune responses remain unclear.
Here, we show that Ets-1 deficiency not
only severely impairs the differentiation and
function of Th1 cells but also leads to overpro-
duction of IL-10. In addition, Ets-1
 
   
 
 Th
cells are unable to induce colitis in SCID mice,
an animal model of Th1 cell–mediated disease.
 
The online version of this article contains supplemental material.
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Abbreviations used: ChIP, 
chromatin immunoprecipita-
tion; Ets-1, E26 transformation–
specific-1; ICS, intracellular 
cytokine staining; ISRE, IFN-
stimulated response element. 
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Ets-1 is required for the expression of T-bet in Th1 cells and
cooperates with T-bet to induce IFN-
 
 
 
 production. To-
gether, our data demonstrate that Ets-1 plays an important and
complex role in mounting effective Th1 immune responses.
 
RESULTS
Ets-1–deficient T cells proliferate normally in the presence 
of CD28 costimulation
 
Ets-1
 
   
 
 T cells have been described to proliferate poorly
upon cross-linking of CD3 in vitro (19, 20), but it is unclear
whether the hypoproliferation of Ets-1
 
   
 
 Th cells can be
rescued by IL-2 or costimulatory signals. To address this
question, we purified CD62L
 
 
 
 naive Th cells from Ets-1
 
   
 
mice or wild-type littermates, which were then stimulated in
vitro with anti-CD3 alone or in combination with anti-
CD28 and/or IL-2. In agreement with previous papers, we
found that Ets-1
 
   
 
 Th cells proliferated less robustly in re-
sponse to anti-CD3 stimulation than wild-type Th cells.
However, addition of anti-CD28, but not exogenous IL-2,
fully restored the proliferation of Ets-1
 
   
 
 Th cells (Fig. 1 a).
In all subsequent in vitro experiments, wild-type and Ets-1
 
   
 
Th cells were initially stimulated with 1 
 
 
 
g/ml anti-CD3
and 2 
 
 
 
g/ml anti-CD28 unless indicated otherwise. Under
such conditions, Ets-1
 
   
 
 Th cells proliferated in a manner
comparable to wild-type cells, thereby excluding any con-
founding effects caused by differences in proliferation.
Ets-1 is expressed in peripheral T cells (27). To determine
whether Ets-1 is differentially expressed in subsets of Th cells,
we compared the protein level of Ets-1 in differentiating Th1
and Th2 cells. We found that freshly isolated Th cells already
expressed a significant level of Ets-1 protein, which was tem-
porarily down-regulated after stimulation under both Th1-
and Th2-skewing conditions but was restored 
 
 
 
3 d later. This
expression pattern of Ets-1 is similar to what has been ob-
served in human T cells (28). Nevertheless, the level and ki-
netics of down-regulation/reexpression of Ets-1 were compa-
rable between differentiating Th1 and Th2 cells (Fig. 1 b).
 
Deficiency of Ets-1 results in profound defects in 
Th cytokine production
 
We examined the cytokine profiles of differentiated Ets-1
 
   
 
Th1 and Th2 cells by intracellular cytokine staining (ICS).
At the time of restimulation, 
 
 
 
98% of the differentiated
wild-type and Ets-1
 
   
 
 cells were CD4
 
 
 
TCR
 
 
 
 
 
 Th cells
(Fig. S1 a, available at http://www.jem.org/cgi/content/
full/jem.20041330/DC1). As shown in Fig. 2 (a and b), 
 
 
 
70
and 50% of wild-type Th1 cells were stained positive for IL-2
and IFN-
 
 
 
, respectively, whereas 50 and 65% of wild-type
Th2 cells expressed IL-4 and IL-10, respectively. Ets-1 defi-
ciency resulted in profound defects in the production of IL-2
and IFN-
 
 
 
. Surprisingly, a high percentage (on average 38%)
of Ets-1
 
   
 
 Th1 cells started to produce IL-10, an antiin-
flammatory cytokine that is normally not expressed by Th1
cells. Ets-1
 
   
 
 Th2 cells also displayed a statistically signifi-
cant reduction in the production of IL-4, and Ets-1 defi-
ciency further enhanced IL-10 production in Th2 cells,
which already express a high level of IL-10. Of note, the
production of TGF-
 
 
 
, another antiinflammatory cytokine,
was not altered by Ets-1 deficiency (unpublished data). We
obtained similar results irrespective of whether naive or bulk
CD4
 
 
 
 T cells were used as starting population.
Stimulation with anti-CD3 and anti-CD28 provides a
rather strong signal to naive Th cells compared with antigen-
specific stimulation. To examine the effect of Ets-1 defi-
ciency on Th cell differentiation and function under more
physiologic conditions, we backcrossed Ets-1–deficient mice
to DO11.10 mice, which carry a TCR transgene specific for
an OVA-derived peptide (OVA
 
323-339
 
) presented by I-A
 
d
 
.
Purified CD4
 
 
 
 T cells from Ets-1
 
   
 
 or control DO11.10
mice were stimulated with wild-type splenic APCs and
OVA
 
323-339
 
 under Th1- or Th2-skewing conditions, and the
phenotype of the Th cells was examined by ICS 1 wk later.
At this time, 
 
 
 
98% of the live cells were CD3
 
 
 
 cells ex-
pressing the DO11.10 TCR transgene (Fig. S1 b). As shown
in Fig. 2 c, Ets-1
 
   
 
 DO11.10 Th1 cells still produced con-
siderably less IL-2 and IFN-
 
 
 
 than wild-type cells. In some
experiments, a significant portion (up to 16%) of Th1 cells
started to produce IL-4, a signature cytokine of Th2 cells.
Again, a large number of the Ets-1
 
   
 
 Th1 cells produced
Figure 1. Proliferation of Ets-1    Th cells and the expression of 
Ets-1 in Th1 and Th2 cells. (a) Naive CD62Lhigh Th cells were isolated 
from wild-type (   ) or Ets-1    (   ) mice and stimulated with indi-
cated concentrations of anti-CD3 in the presence or absence of 2  g/ml 
anti-CD28 and/or 100 U/ml recombinant human IL-2 (rhIL-2), and the up-
take of [3H]thymidine was measured. The data shown are representative of 
three independent experiments. (b) Expression of Ets-1 during the differ-
entiation of Th cells. Freshly isolated wild type Th cells were subjected to in 
vitro differentiation under Th1- or Th2-skewing conditions. Cell lysates 
were prepared at indicated time points and analyzed by Western analysis 
using an anti–Ets-1 or anti-HSP90 antibody. 
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IL-10. The abnormal Th1 cytokine profile was also con-
firmed by ELISA when the differentiated Ets-1
 
   
 
 DO11.10
Th1 cells were restimulated with OVA
 
323-339
 
/APCs for 24 h
(Fig. 2 d). Thus, the aberrant differentiation and function of
Ets-1
 
   
 
 Th1 cells is independent of genetic background or
mode of stimulation. The cytokine profile of Ets-1
 
   
 
DO11.10 Th2 cells as determined by ICS (i.e., reduced IL-4
and enhanced IL-10 production) was comparable to our ear-
lier findings. However, the impairment in the production of
IL-4 by Ets-1
 
   
 
 Th2 cells was much more significant upon
restimulation with OVA/APCs (Fig. 2 d), indicating the ef-
fect of Ets-1 deficiency on Th2 cells may quantitatively de-
pend on mode of stimulation.
 
Figure 2. Dysregulated cytokine production of Ets-1
 
   
 
 Th cells.
 
 
(a and b) Freshly isolated wild-type (
 
   
 
) or Ets-1
 
   
 
 (
 
   
 
) Th cells were 
subjected to in vitro differentiation under Th1- or Th2-skewing conditions 
and restimulated with PMA/ionomycin on the seventh day after initial 
stimulation. The production of indicated cytokines was determined by ICS. 
(a) Results obtained from a typical experiment are shown and the numbers 
represent the percentages of cells that were stained positive with the indi-
cated anticytokine antibodies. (b) Cumulative results of 
 
 
 
15 experiments 
are shown. Each black or white circle represents one wild-type or Ets-1
 
   
 
 
mouse, respectively. The horizontal bars denote the average percentages 
of cytokine positive cells. The results of a paired Student’s 
 
t
 
 test comparing 
Ets-1
 
   
 
 and littermate controls are shown. (c and d) Th cells were isolated 
from wild-type or Ets-1
 
   
 
 DO11.10 mice and stimulated with OVA
 
323-339
 
 
and wild-type splenic APCs under Th1- or Th2-skewing conditions. After 7 d 
in culture, the differentiated Th cells were restimulated with PMA/ionomycin 
for 4 h (c) or with OVA
 
323-339
 
/APCs for 24 h (d), and the production of cy-
tokine was examined by ICS (c) or ELISA (d), respectively.
Figure 3. IL-10R blockade does not rescue the defective cytokine 
production by Ets-1    Th1 cells. (a) Aliquots of culture supernatant 
were harvested from differentiating wild-type or Ets-1    cells (as in Fig. 2 
a) 48 h after initial stimulation under Th1-skewing conditions, and the 
levels of indicated cytokines were measured by ELISA. The level of IL-2 in 
Ets-1    Th cultures ranged between 1–4 ng/ml. (b) Freshly isolated wild-
type and Ets-1    Th cells were stimulated as described in Fig. 2 a except 
that 10  g/ml anti–IL-10R antibody (open symbols) or control IgG (closed 
symbols) was added. The differentiated Th cells were restimulated with 
PMA/ionomycin on day 7, and the production of cytokines was measured 
by ICS. The horizontal bars represent the average values of three indepen-
dent experiments. 
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Because IFN-
 
 
 
 promotes the differentiation of Th1 cells
via a positive feedback mechanism, it is possible that the im-
paired cytokine production by Ets-1
 
   
 
 Th1 cells is caused
by a defect in the expression of IFN-
 
 
 
 during early stages of
Th1 differentiation. Therefore, we examined the cytokine
production by differentiating Ets-1
 
   
 
 Th1 cells 48 h after
initial stimulation. We found that the levels of IFN-
 
 
 
 were
comparable between wild-type and Ets-1
 
   
 
 Th1 cells at this
early time point, whereas the aberrant production of IL-2
and IL-10 was already apparent (Fig. 3 a). Thus, Ets-1 is dis-
pensable for the early secretion of IFN-
 
 
 
 by differentiating
Th1 cells, but controls IFN-
 
 
 
 production in terminally dif-
ferentiated Th1 cells. These data also indicate that the aber-
rant cytokine production by Ets-1
 
   
 
 Th1 cells is not caused
by an early defect in IFN-
 
 
 
 production.
IL-10 is known to inhibit Th1 differentiation, mostly indi-
rectly by affecting APC function, although direct effects on T
cells have been reported (29, 30). To test whether the early IL-
10 overproduction by Ets-1
 
   
 
 Th cells was responsible for
their altered cytokine profile, we repeated the in vitro differen-
tiation of Th cells in the presence of an anti–IL-10 receptor an-
tibody. As shown in Fig. 3 b, addition of anti–IL-10R antibody
increased the production of IL-4 and IL-5 by Ets-1
 
   
 
 Th2
cells to a level comparable to that of wild-type Th2 cells in the
absence of anti–IL-10R antibody, although still lower than that
of wild-type Th2 cells in the presence of anti–IL-10R anti-
body. Addition of anti–IL-10R antibody also modestly reduced
the level of IL-10 in Ets-1
 
   
 
 Th1 cells. In contrast, IL-10R
blockade only had negligible effects on the levels of IL-2 and
IFN-
 
 
 
. Thus, deficiency of Ets-1 impairs the production of
IL-2 and IFN-
 
 
 
 by an IL-10–independent mechanism.
Homologous recombination at the Ets-1 locus might also
disturb the expression of other genes, thereby causing the
aberrant cytokine profile of Ets-1
 
   
 
 Th1 cells. In addition,
it is unclear whether reconstitution of Ets-1 is sufficient to
normalize the production of cytokines by Ets-1
 
   
 
 Th1 cells
once the process of differentiation has been set into motion.
To address these questions, we infected differentiating Ets-
1
 
   
 
 Th1 cells with a bicistronic retrovirus encoding either
GFP alone or together with Ets-1 36 h after the initial stim-
ulation. As shown in Fig. 4 a, retroviral Ets-1 completely or
nearly completely restored the production of IFN-
 
 
 
 and IL-2
upon secondary stimulation, and concurrently attenuated the
production of IL-10. Therefore, the aberrant cytokine pro-
duction by Ets-1
 
   
 
 Th1 cells is reversible and is indeed
caused by the deficiency of Ets-1. In contrast, overexpres-
sion of Ets-1 did not substantially influence the expression of
cytokines by wild-type Th1 cells (Fig. 4 b), which already
express a high level of endogenous Ets-1.
 
Ets-1
 
   
 
 Th cells do not induce colitis in SCID mice
 
Our in vitro findings suggest that Ets-1 is required for optimal
production of inflammatory cytokines by Th1 cells while sup-
pressing antiinflammatory IL-10. To investigate the in vivo ef-
fect of Ets-1 deficiency on Th1-driven inflammatory re-
sponses, we chose a mouse model of inflammatory bowel
disease that is induced by transferring CD45RB
 
high
 
 Th cells
into SCID mice. The development of colitis in this model de-
pends on IFN-
 
 
 
 and is inhibited by IL-10 (31). More impor-
tantly, this model allowed us to specifically examine the func-
tion of Ets-1
 
   
 
 Th cells, in a “wild-type” environment.
Wild-type or Ets-1
 
   
 
 CD45RB
 
high
 
 Th cells were puri-
fied by a Mo-Flo sorter and were injected into SCID mice,
which were weighed weekly to monitor the activity of the
disease. As shown in Fig. 5 a and Table I, all of the animals
continued to gain weight at comparable rates up to 5 wk af-
ter Th cell transfer. Thereafter, the weight of mice that had
received wild-type cells dropped substantially, eventually be-
low the starting weight. In contrast, uninjected mice and
mice that had received Ets-1
 
   
 
 Th cells continued to gain
weight at comparable rates until 10 wk after transfer when
the mice were killed. Histological examination revealed
marked inflammation in the mucosal and submucosal layers
Figure 4. Overexpression of Ets-1 normalizes the production of 
cytokines by Ets-1    Th1 cells. (a) Freshly isolated Ets-1    or wild-
type Th cells were stimulated in vitro under Th1-skewing conditions. 36 h 
after the initial stimulation, the differentiating Th1 cells were transduced 
with GFP-RV/Ets-1 or empty GFP-RV retroviruses. The cells were restimu-
lated with PMA/ionomycin on the seventh day, and the production of cy-
tokines was determined by ICS. The cells were separated into transduced 
(GFP ) and nontransduced (GFP ) populations, and the staining of indi-
cated cytokines was displayed as histograms. The numbers represent the 
percentages of cells that are stained positive for indicated cytokines. 
(b) Wild-type Th cells were stimulated as described before and infected 
with GFP-RV/Ets-1. The production of indicated cytokines by transduced 
(GFP ) and nontransduced (GFP ) Th1 cells was determined by ICS as 
described before. 
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of the colons of mice that had received wild-type Th cells.
In contrast, we observed no such inflammation in uninjected
mice or in mice that had been injected with Ets-1
 
   
 
 Th
cells (Fig. 5 b and not depicted).
To examine the cytokine profile of the donor cells, we
recovered CD4
 
 
 
 T cells from the mesenteric lymph nodes
of the recipient animals. The recovered Ets-1
 
   
 
 and wild-
type donor Th cells expressed comparable levels of several
memory and activation markers, such as CD69 and CD44
(unpublished data), indicating antigen encounter in vivo.
The recovered Th cells were restimulated with anti-CD3 in
vitro and the production of cytokines was measured by
ELISA. Similar to our earlier findings, Ets-1
 
   
 
 Th cells pro-
duced virtually no IFN-  or IL-2 and a significantly elevated
level of IL-10, whereas the production of IL-4 was compara-
ble between Ets-1    and wild-type cells (Fig. 5 c). These
results firmly demonstrate that deficiency of Ets-1 also leads
to defective Th1 cell–mediated inflammation in vivo.
Ets-1 promotes the differentiation and function of Th1 cells 
via multiple mechanisms
Thus far, our data indicate that the differentiation and func-
tion of Th1 cells are severely impaired in the absence of
Ets-1. The molecular events regulating the differentiation and
function of Th1 cells have been characterized recently. Naive
Th cells produce small amounts of both IL-4 and IFN- 
upon primary stimulation (32). IFN- /STAT1 signals induce
the expression of T-bet, which in turn strengthens IFN-  ex-
pression and drives Th1 differentiation (13). T-bet also in-
duces the expression of the IL-12R 2 chain, thus enabling
Figure 5. Ets-1    Th cells do not induce colitis in SCID mice. SCID 
mice were injected with 3   105 wild-type (   ) or Ets-1    (   ) 
CD45RBhigh Th cells as described in Materials and methods or received no 
cells. (a) The body weight of the host SCID mice was monitored weekly. 
The data shown are representative of two independent experiments with 
five mice/group each. (b) 10 wk after cell transfer, mice were killed and the 
large intestines were removed. Cross sections of fixed large intestines of 
the host SCID mice were stained with hematoxylin and eosin. The high 
power views of the boxed areas (top) are shown in the two bottom panels. 
The size of the box is 0.6   0.6 mm. (c) MLN cells from the host SCID mice 
within the same experimental group were pooled, and CD4  T cells were 
purified. The cells were restimulated in vitro with 1  g/ml anti-CD3 for 48 h, 
and the production of the indicated cytokines was measured by ELISA.
Table I. Weight development of SCID mice after injection of WT or 
Ets-1    (KO) CD4 CD45RBhigh cells
Day
Group Mouse 0 7 14 21 28 35 42 46 58 64 70
No
cells
1 18.8 20.3 20.0 19.5 20.3 19.9 20.6 20.3 20.3 20.8 21.6
2 16.4 17.4 18.4 18.4 18.9 18.9 19.3 19.3 19.0 19.4 19.4
3 18.2 19.5 20.0 20.4 20.2 21.3 21.3 20.5 20.7 21.1 21.4
4 16.7 18.0 18.7 19.2 18.9 19.1 18.9 19.9 19.4 20.1 20.6
5 17.7 18.8 18.8 19.3 20.2 20.4 22.2 22.0 20.7 20.9 21.1
mean 17.6 18.8 19.2 19.4 19.7 19.9 20.5 20.4 20.0 20.5 20.8
SE 0.5 0.6 0.4 0.4 0.4 0.5 0.7 0.5 0.4 0.4 0.4
WT
1 18.5 19.3 19.5 19.6 20.2 20.8 20.6 19.6 16.1 16.1 15.6
2 20.4 21.1 21.2 20.6 21.3 21.9 21.4 21.2 18.5 18.5 17.9
3 16.9 18.0 17.6 18.0 17.9 17.9 17.4 16.5 15.2 14.6 14.9
4 17.7 17.9 18.4 18.5 18.9 19.1 19.3 19.7 16.5 16.1 16.2
5 18.9 19.2 20.8 19.8 19.6 20.5 19.5 19.5 19.2 19.5 19.4
mean 18.5 19.1 19.5 19.3 19.6 20.0 19.6 19.3 17.1 17.0 16.8
SE 0.7 0.6 0.8 0.5 0.6 0.8 0.8 0.9 0.8 1.0 0.9
KO
1 18.3 18.5 18.8 19.1 19.5 20.3 20.2 20.6 19.9 20.4 20.2
2 17.9 19.0 19.2 19.7 20.0 21.0 21.2 22.3 20.5 21.1 21.4
3 20.9 20.7 20.6 20.8 21.1 22.5 23.0 23.2 21.3 22.4 22.5
4 17.7 18.3 18.1 18.9 19.6 16.8 18.0 17.9 18.3 18.6 19.2
5 17.2 17.9 18.3 18.9 19.6 19.9 19.6 20.4 19.9 20.1 20.3
mean 18.4 18.9 19.0 19.5 20.0 20.1 20.4 20.9 20.0 20.5 20.7
SE 0.7 0.5 0.5 0.4 0.3 1.0 0.9 1.0 0.6 0.7 0.6
The weight (in grams) of individual mice (nos. 1–5) at the indicated time points is 
shown. Mean values and standard error (SE) as used in Fig. 5 are shown as well.ETS-1 IS ESSENTIAL FOR TH1 INFLAMMATORY RESPONSES | Grenningloh et al. 620
IL-12 to further promote Th1 differentiation via STAT4 sig-
naling (11). Ets-1 deficiency may interfere with either one or
both pathways. Alternatively, Ets-1 may control the differen-
tiation and IFN-  production via a novel mechanism inde-
pendent of IL-12/STAT4 and IFN- /STAT1/T-bet.
Because we used IL-12 in our culture system to drive
Th1 differentiation, we first examined the expression and
phosphorylation of STAT4. As naive Th cells express very
little IL-12R 2 chain, which is induced by TCR signals in a
T-bet–dependent manner, we cultured Th cells under Th1-
or Th2-skewing conditions for 72 h before treating the cells
with IL-12. Very little phosphorylated STAT4 (p-STAT4)
was detected in the absence of IL-12 (Fig. 6 a, lanes 1–4).
Addition of IL-12 quickly induced phosphorylation of
STAT4 in wild-type Th cells and the level of p-STAT4 was
much higher in Th1 than in Th2 cells (Fig. 6 a, lanes 5 and
7). Interestingly, we found that the level of p-STAT4 was
modestly reduced in Ets-1    Th1 cells (Fig. 6 a, lanes 5 and
6). The difference in the level of p-STAT4 between differen-
tiating wild-type and Ets-1    Th cells was detected as early
as 24 h, but most prominent at 48–96 h after primary stimula-
tion (Fig. S2 a, available at http://www.jem.org/cgi/content/
full/jem.20041330/DC1). The reduction in the level of
p-STAT4 could be attributed to either a lower level of total
STAT4, IL-12R, or both. We found that total STAT4 levels
were indeed reduced in Ets-1    Th1 cells at 48–96 h after
Figure 6. Regulation of IFN-  production in Ets-1    Th cells. 
(a) Analysis of the IL-12–STAT4 signaling pathway. Wild-type and Ets-1    
Th cells were stimulated in vitro with anti-CD3/anti-CD28 under Th1- or 
Th2-skewing conditions for 72 h and treated with 10 ng/ml IL-12 for 20 min 
or left untreated (n.s.). Whole cell lysates were prepared and subjected to 
Western analyses with the indicated antibodies. (b) Wild-type or Ets-1    Th 
cells were stimulated using either IL-12 or IFN-  as Th1-skewing cytokine. 
After 7 d of culture, the cells were restimulated with PMA/ionomycin and 
the cytokine production was measured by ICS. (c–e) Analyses of IFN- –
STAT1–T-bet pathway. (c) Freshly isolated wild-type and Ets-1    Th cells 
were treated with 10 ng/ml IFN-  for 20 min or left untreated (n.s.). Whole 
cell lysates were subjected to Western analysis with the indicated antibod-
ies. (d) Wild-type or Ets-1    Th cells were stimulated under Th1-skewing 
conditions. At different time points, total cell lysates were prepared, and 
T-bet expression was analyzed by Western blot. (e) Wild-type and Ets-1    
Th cells were subjected to in vitro differentiation under Th1-skewing condi-
tions, either with IL-12 or IFN- , or Th2-skewing conditions for 72 h. Nu-
clear extracts were prepared and the levels of T-bet were determined by 
Western analysis. (f) Th1 cells obtained by in vitro differentiation were left 
untreated (n.s.) or treated with PMA/ionomycin. At the indicated time 
points, the T-bet expression was determined by Western analysis in total 
cell lysates. (g) Th cells of the indicated genotypes were stimulated in vitro 
under Th1-skewing conditions and infected with GFP-RV/T-bet retroviruses 
36 h after initial stimulation. The infected Th1 cells were restimulated on 
day 7 and the production of IFN-  was examined by ICS. GFP-negative 
(nontransduced) and GFP-positive (transduced) populations were sepa-
rately gated, and the staining of IFN-  was displayed as histograms. The 
numbers represent the percentage of cells stained positive for IFN- .JEM VOL. 201, February 21, 2005 621
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stimulation (Fig. 6 a and Fig. S2 a). In addition, these cells
also expressed lower levels of IL-12R 2 transcript (Fig. S2
b). Together, these data suggest that Ets-1 is required for the
up-regulation of both STAT4 and IL-12R 2 during Th1
differentiation, and thus for proper IL-12 signaling.
If the impaired IL-12 signaling is the main cause of de-
fective Th1 differentiation in the absence of Ets-1, then Ets-1
deficiency should not affect the differentiation of Th1 cells
in an IL-12–free system. However, when we used IFN- 
instead of IL-12 to drive Th1 differentiation (thus eliminat-
ing any role of IL-12/STAT4 in our system), we still ob-
served the same defect in cytokine production by Ets-1   
Th1 cells upon secondary stimulation (Fig. 6 b). This result
argues strongly for the presence of IL-12/STAT4-indepen-
dent mechanisms mediating the effects of Ets-1 deficiency.
Next, we investigated whether the IFN- –STAT1–T-bet
pathway was intact in Ets-1    Th cells. Freshly isolated
Ets-1    Th cells contained a normal amount of STAT1
proteins and were capable of phosphorylating STAT1 upon
exposure to IFN-  (Fig. 6 c), indicating intact IFN- /
STAT1 signaling in Ets-1    Th cells. Next, we examined
the levels of T-bet in developing Ets-1    Th1 cells at differ-
ent time points after primary stimulation with anti-CD3 and
anti-CD28. In agreement with the normal IFN- /STAT1
signaling and normal early IFN-  production (Fig. 3 a), dif-
ferentiating Ets-1    Th1 cells only had a very negligible re-
duction in the level of T-bet (Fig. 6 d). This was indepen-
dent of whether IL-12 or IFN-  were used as Th1-skewing
cytokines (Fig. 6 e). Resting differentiated Th1 cells ex-
pressed very little T-bet, which was induced by stimulation
with PMA/ionomycin in wild-type Th1 cells. Interestingly,
the expression of T-bet was markedly impaired in Ets-1   
Th1 cells (Fig. 6 f). The defect in T-bet expression upon
secondary stimulation may well explain the impaired func-
tion of Ets-1    Th1 cells. Therefore, we tested whether re-
storing the expression of T-bet could overcome the effects
of Ets-1 deficiency. Wild-type or Ets-1    Th cells were
stimulated under Th1-skewing conditions and infected with
a bicistronic retrovirus encoding both T-bet and GFP 36 h
later. After 6 d of culturing, cytokine production was ana-
lyzed by ICS. Overexpression of T-bet in wild-type Th1
cells, which already expressed a high level of T-bet, further
raised the percentage of IFN- –producing cells from 33 to
52%. But to our surprise, retroviral T-bet had absolutely no
effect on the production of IFN-  by Ets-1    Th1 cells
(Fig. 6 g). This observation indicates that the function of
T-bet is severely compromised in the absence of Ets-1 and led
us to hypothesize either that Ets-1 may directly or indirectly
transactivate the IFN-  promoter independently of T-bet or
that Ets-1 may function as a cofactor enhancing the activity
of T-bet.
Ets-1 is recruited to the IFN-  promoter and enhances 
the function of T-bet
To distinguish between the aforementioned scenarios, we
transfected 293T cells with a reporter construct containing
Figure 7. Functional synergy between T-bet and Ets-1. (a) 293T cells 
were transfected with a reporter plasmid containing the wild-type mouse 
IFN-  promoter (WT), a mutated EBS or ISRE, or a double mutation (EBS/ISRE). 
Additionally, the cells were transfected with the indicated expression vectors 
encoding His-tagged T-bet (Tbet-His), FLAG-tagged Ets-1 (Ets1-flag), or the 
corresponding empty control vectors (pHis or pflag). The firefly luciferase ac-
tivities were first normalized against renilla luciferase activities obtained from 
an internal control pRL-TK vector. The normalized activity obtained with the 
reporter plasmid and empty expression vectors was arbitrarily set as 1. The 
data shown are the average of at least three independent experiments. (b) The 
structure of the mIFN-  reporter plasmid containing 564 bp of the promoter 
region plus 112 bp downstream of the transcriptional start site is shown. The 
positions of the T-bet binding Brachiury site (Bra), the putative IFN-stimulated 
response element (ISRE) and the Ets binding site (EBS) are shown in the lower 
part. Arrows indicate the positions of the primers used for ChIP analysis. (top) 
The sequences of the binding sites and the corresponding sequences of the 
rat and human promoters. The core GGAA motifs are shaded. (c) Wild-type Th 
cells were differentiated toward Th1, stimulated with PMA/ionomycin, and 
subjected to ChIP analysis. Chromatin was precipitated with anti–Ets-1 or 
anti–T-bet antibody, or no antibody as negative control. The precipitated DNA 
was amplified using primers (b, arrows) specific for a 220-bp fragment of the 
IFN-  promoter spanning the three binding sites. As negative control, primers 
specific for a portion of Ets-1 intron 2/exon 3 were used. As positive control, 
total DNA was diluted 1:100 and used in the PCR (input).ETS-1 IS ESSENTIAL FOR TH1 INFLAMMATORY RESPONSES | Grenningloh et al. 622
 564 to  112 bp of the mouse IFN-  promoter. This pro-
moter region had been shown previously to confer Th1-
selective expression (33). Additionally, the cells were trans-
fected with expression vectors for Ets-1, T-bet, or both.
Recently, a Brachiury site at  66 bp has been shown to be
critical for transactivation of this promoter by T-bet (34). As
shown in Fig. 7 a (top left, WT), the IFN-  reporter con-
struct could be transactivated by T-bet more than fivefold
compared with the background activity. Overexpression of
Ets-1 alone had a negligible effect on the promoter, but sig-
nificantly enhanced the promoter activity in the presence of
T-bet. These results not only demonstrate the functional
synergy between T-bet and Ets-1 but also argue that Ets-1
can serve as a cofactor of T-bet. Similar results were ob-
tained when we used a human IFN-  reporter construct
containing the entire human IFN-  gene (7) in both 293T
and EL4 cells (unpublished data).
The functional synergy between T-bet and Ets-1 may be
dependent on their physical interaction. However, we have
thus far been unable to demonstrate the existence of an Ets-1/
T-bet complex in Th cells by coimmunoprecipitation (un-
published data). Alternatively, Ets-1 may be recruited to the
vicinity of the Brachiury site in the IFN-  promoter without
direct physical interaction with T-bet. To test this hypothesis,
we performed chromatin immunoprecipitation (ChIP) on
wild-type Th1 cells using an Ets-1–specific antibody. The
precipitated DNA was amplified using primers flanking the
Brachiury site (Fig. 7 b, arrows). As shown in Fig. 7 c, both
Ets-1 and T-bet were recruited to the proximal region of the
endogenous IFN-  promoter. As a negative control, no re-
cruitment of Ets-1 or T-bet to the second intron/third exon
of the Ets-1 gene was detected by ChIP analysis (Fig. 7 c).
Sequence analysis of the mouse IFN-  promoter did not
uncover any conventional Ets-1 binding sites, but revealed a
putative binding site for Ets proteins at  23 bp. Similar
binding sites were also found in the promoters of the rat and
human IFN-  gene (Fig. 7 b). In addition, a putative IFN-
stimulated response element (ISRE) is located at  175 bp.
Consensus ISRE sites also contain the GGAA motif and
have been reported to bind Ets-1 (35). To determine
whether the EBS and/or ISRE were needed to mediate the
functional synergy between Ets-1 and T-bet, we generated
several IFN-  promoter/reporters bearing a mutation in the
 23 EBS,  175 ISRE, or both sites and repeated the lu-
ciferase assays (Fig. 7 a). None of the mutations affected the
T-bet–induced transactivation but mutation in the  175
ISRE or both sites nearly completely abrogated the func-
tional synergy between Ets-1 and T-bet. In contrast, muta-
tion in the  23 EBS alone had no effect on the promoter
activity. Together, these results depict that Ets-1 is recruited
to the proximal region of the IFN-  promoter and enhances
the activity of T-bet via the  175 ISRE.
DISCUSSION
The differentiation of Th1 cells and the coordination of in
vivo Th1 responses requires a number of important tran-
scription factors, both T cell–specific and more widely ex-
pressed (14, 36–40). Our data demonstrate that Ets-1 pro-
motes the differentiation and function of Th1 cells by several
nonmutually exclusive mechanisms. Ets-1 is required for
proper up-regulation of IL-12R 2 and STAT4 during the
differentiation of Th1 cells. However, the differentiation and
function of Ets-1    Th1 cells is still markedly compromised
in an IL-12/STAT4-free system, arguing against a decisive
role of IL-12/STAT4, at least in vitro. Ets-1 also controls
the level of T-bet in Th1 cells in a differentiation stage-
dependent manner. Deficiency of Ets-1 only negligibly af-
fects the expression of T-bet in differentiating Th1 cells, but
significantly impairs the induction of T-bet in fully differ-
entiated Th1 cells. However, forced expression of T-bet
through retroviral transduction did not rescue the differenti-
ation and function of Ets-1    Th1 cells. These observations
led us to discover that Ets-1 is required for the function of
T-bet. In the absence of Ets-1, the IFN- –promoting effect
of T-bet is severely impaired. Thus, Ets-1 can be considered
as a functional cofactor of T-bet.
IL-2/STAT5 was recently shown to influence the differ-
entiation of Th cells (41). Ets-1    Th cells produced a low
level of IL-2 even during primary stimulation, raising the
possibility that the aberrant differentiation of Ets-1    Th
cells may be at least partly attributed to a low level of IL-2.
To rule out this possibility, we repeated the in vitro differ-
entiation, adding recombinant IL-2 at the very beginning
instead of 24 h after stimulation. We still observed the
same defect in cytokine production by Ets-1    Th cells
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20041330/DC1). Thus, Ets-1 does not influence the
differentiation of Th cells indirectly through IL-2/STAT5.
As retroviral T-bet could not rescue the production of IFN- 
by Ets-1    Th1 cells, we believe that the lack of T-bet/
Ets-1 synergy is the main, but not the only, reason for the
defective IFN-  production by Ets-1    Th1 cells. To the
best of our knowledge, Ets-1 is thus far the only transcrip-
tion factor that is necessary for T-bet to exert its function.
Although our data indicate that the functional synergy
between T-bet and Ets-1 is mediated by the  175 ISRE,
we have not completely ruled out the possibility that Ets-1
directly interacts with T-bet. Ets-1 has been found to physi-
cally interact with several nuclear proteins, including NFAT,
AP1, and STAT5 (23, 42, 43), which can modulate the ac-
tivity of Ets-1. The physical interaction between Ets-1 and
T-bet may be too weak to be detected by coimmunoprecip-
itation. We would also like to point out that the interplays
between T-bet and Ets-1 may extend beyond the IFN- 
gene and Th1 differentiation. Both Ets-1 and T-bet are es-
sential for the development of NKT cells (44, 45). This ob-
servation suggests the presence of other common target
genes. Alternatively, Ets-1 could also regulate the expression
of T-bet in NKT cells. Unfortunately, the tissue-specific
and/or functionally critical cis-acting elements of the T-bet
gene have not been identified, precluding further analyses on
how Ets-1 may regulate the expression of T-bet.JEM VOL. 201, February 21, 2005 623
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Why are Ets-1    Th cells unable to induce colitis in
SCID mice? The development of colitis in SCID mice de-
pends on the production of IFN-  and TNF-  by transferred
Th cells and can be inhibited by IL-10 (31, 46). The cytokine
profile of Ets-1    Th cells recovered from SCID mice is ob-
viously counterproductive for the development of colitis.
However, it is still unclear whether it is the reduction in
IFN- , overproduction of IL-10, or a combination of both
that protects the SCID mice from developing colitis. It has
been shown that Th cells engineered to produce IL-10 do
not induce colitis in a model similar to the one we used (46).
One approach to addressing this question is the generation of
Ets-1/IL-10 double-deficient mice. If the overproduction of
IL-10 is responsible for the inability of Ets-1    Th cells
to induce colitis, CD45RBhigh Th cells from these double
knockout mice should be able to induce colitis. More re-
cently, it has been demonstrated that regulatory T cells are
capable of inhibiting colitis induced by CD45RBhigh Th cells
in SCID mice (47–49). Ets-1    Th cells bear several features
of the type 1 regulatory T cells, including overproduction of
IL-10 and poor production of IL-2, raising an intriguing pos-
sibility that Ets-1    Th cells possess the activity of regulatory
T cells. This possibility is currently under investigation.
We have yet to determine how Ets-1 suppresses the ex-
pression of IL-10. The regulation of IL-10 expression in Th
cells is not well understood (30). It has been shown that the
expression of IL-10 can be controlled both at the transcrip-
tional level by Sp1 and Sp3, and at the posttranscriptional
level by mRNA stability (50, 51). Our unpublished data in-
dicate that Ets-1 suppresses the expression of IL-10 at least
partly at the transcriptional level. It is known that IFN-  can
suppress the expression of Th2 cytokines, including IL-10,
raising the possibility that the overproduction of IL-10 by
Ets-1    Th cells may be secondary to a low level of IFN- .
However, the following observations argue strongly against
this scenario. First, in Fig. 3 a, we show that differentiating
Ets-1    Th1 cells already produced much more IL-10 after
primary stimulation, when the production of IFN-  was
normal. Second, Ets-1    Th1 still produced more IL-10
than wild-type cells when differentiated in the presence of
IFN-  instead of IL-12 (Fig. S4 a, available at http://
www.jem.org/cgi/content/full/jem.20041330/DC1) or when
restimulated with PMA/ionomycin plus IFN-  (Fig. S4 b).
Finally, STAT1    DO11.10 Th1 cells, which also have a
defect in IFN-  production, do not express more IL-10 than
wild-type DO11.10 Th1 cells (11). Therefore, the overpro-
duction of IL-10 is a unique feature of Ets-1 deficiency and
is not caused by an insufficient amount of IFN- .
Although Ets-1    Th2 cells obtained by in vitro differ-
entiation also produced less IL-4, Ets-1    Th cells recov-
ered from the SCID mice were capable of expressing IL-4 at
a level comparable to that of wild-type Th cells. This dis-
crepancy may arise from the differences in microenviron-
ment between in vitro (as in the in vitro differentiation) and
in vivo (as in the SCID colitis model) priming or in mode of
stimulation. Thus, the effect of Ets-1 deficiency on the func-
tion of Th2 cells in vivo is still unclear and warrants further
investigation.
In summary, we found that Ets-1 has a very broad and
profound influence on Th immune responses. Ets-1 not only
is essential for mounting Th1 inflammatory responses but
also suppresses the expression of the antiinflammatory cyto-
kine IL-10. The ability of Ets-1 to influence the decision be-
tween inflammatory and antiinflammatory Th immune re-
sponses makes it a potential therapeutic target for various
Th1-mediated autoimmune diseases, such as Crohn’s disease
or multiple sclerosis.
MATERIAL AND METHODS
Mice. Ets-1    mice have been described previously (18). Heterozygous
mice on a mixed C57BL/6 and 129SV background were intercrossed to
generate Ets-1    and wild-type littermate control mice. For antigen-spe-
cific stimulation, the mice were backcrossed to DO11.10 mice (24) for four
generations before being intercrossed. The animals were housed under spe-
cific pathogen-free conditions, and experiments were performed in accor-
dance with the institutional guidelines for animal care at Dana-Farber Can-
cer Institute under approved protocols. Male or female mice aged 6–8 wk
were used. In all experiments, wild-type littermates were used as controls.
For the colitis model, female, 6–8-wk-old B6-CB17-PrkdcSCID mice were
obtained from The Jackson Laboratory as were DO11.10 mice.
Cell purification and in vitro differentiation of Th cells. CD4  T cells
were purified from spleens and lymph nodes by magnetic cell sorting
(Miltenyi Biotec). For most experiments, total CD4  T cells were purified
using anti-CD4–coupled magnetic beads. For some experiments, naive
CD4  T cells were purified in two steps. First, total CD4  cells were iso-
lated using FITC-labeled anti-CD4 (BD Biosciences) and anti-FITC–cou-
pled beads (Miltenyi Biotec). The beads were enzymatically released, and
naive CD4  T cells were enriched using anti-CD62L–coated magnetic
beads (Miltenyi Biotec). The purity of the isolated CD4 CD62Lhigh cells
was  90%. The cells (2   106/ml) were stimulated with 1  g/ml plate-
bound anti-CD3 and 2  g/ml soluble anti-CD28 under Th1-skewing (3
ng/ml IL-12 plus 10  g/ml anti–IL-4) or Th2-skewing (10 ng/ml IL-4 plus
10  g/ml anti–IFN- ) conditions. In some experiments, IL-12 was re-
placed with 10 ng/ml IFN- . For IL-10–blocking experiments, 10  g/ml
anti–IL-10R was added on day 0 and again on day 2. 100 U/ml recombi-
nant human IL-2 (rhIL-2) was added after 24 h, and the cells were ex-
panded in complete medium containing IL-2 for 7 d. On day 7, the cells
were restimulated with 50 ng/ml PMA and 1  M ionomycin. The produc-
tion of cytokines was examined by ICS. For antigen-specific stimulation,
2.5   105 CD4  T cells from wild-type or Ets-1–deficient DO11.10 mice
were stimulated with 5   106 irradiated (3,000 rad) splenic APCs obtained
from BALB/c mice and 0.3  M OVA323-339 under Th1- or Th2-skewing
conditions. Skewing conditions were the same as with the anti-CD3–stimu-
lated cultures, except for the use of anti–IL-12 instead of anti–IFN-  for
Th2 cells. IL-2 was added after 72 h, and the cells were cultured for a total
of 7 d before their cytokine profile was tested. Recombinant human IL-2
and anti–IL-4 (11B11) were provided by the National Cancer Institute,
Preclinical Repository. IL-4 and IL-12 were purchased from PeproTech.
NA/LE-grade anti–IFN-  (XMG1.2), anti-CD3 (2C11), anti-CD28
(37.51), anti–IL-12 (C17.8), and anti–IL-10R (1B1.3a) were obtained from
BD Biosciences.
ICS. The protocol for ICS has been described previously (10). The follow-
ing antibodies were purchased from BD Biosciences: anti–IL-2 FITC
(JES6-5H4), anti–IL-4 PE (11B11), anti–IL-5 PE (TRFK5), anti–IL-10
FITC, or PE (JES5-16E3), and anti–IFN-  FITC (XMG1.2). The stained
cells were subjected to flow cytometric analysis on a FACScan (BD Bio-
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ELISA. Freshly isolated or differentiated Th cells were stimulated as indi-
cated. Cytokines were quantified by sandwich ELISA using the following
monoclonal antibody pairs (BD Biosciences): anti–IL-2 (JES6-1A12)/bi-
otin-anti–IL-2 (JES6-5H4), anti–IL-4 (11B11)/biotin-anti–IL-4 (BVD6-
24G2), anti–IL-10 (JES5-2A5)/biotin-anti–IL-10 (JES5-16E3), and anti–
IFN-  (R4-6A2)/biotin-anti–IFN-  (XMG1.2).
SCID colitis model. Spleen and lymph node cells from female wild type
or Ets-1    mice were labeled with anti–CD4-PE (RM4-5) and anti–
CD45RB-FITC (16A). CD4 CD45RBhigh Th cells were sorted using a
Mo-Flo cell sorter. 8-wk-old female B6-CB17-PrkdcSCID mice were in-
jected intravenously with 3   105 sorted cells per mouse. The injected mice
were weighed weekly for 10 wk before being killed. The large intestines of
the host animals were fixed with 10% formalin and paraffin embedded, and
the cross sections were stained with hematoxylin and eosin.
Retroviral transduction of Th cells. The protocol for retroviral trans-
duction of Th cells has been described previously (25). In brief, differentiat-
ing Th cells were infected  36 h after primary stimulation. The infected
cells were washed once, replated in fresh complete skewing medium, and
cultivated for another 6 d before analysis. The bicistronic vectors GFP-RV
and GFP-RV/T-bet were described previously and were gifts from G. No-
lan (Stanford University, Stanford, CA) and L. Glimcher (Harvard School
of Public Health, Boston, MA), respectively (7). GFP-RV/Ets-1 was con-
structed by cloning a full-length murine Ets-1 cDNA, fused at the NH2 ter-
minus with a FLAG tag, into the BglII site of the GFP-RV vector.
Luciferase assays and site-specific mutagenesis. For luciferase assays,
the adenovirus-transformed human kidney cell line 293T was cultured in
DMEM plus 10% FCS. 1 d before transfection, the cells were seeded into 24-
well plates at 105 cells/well. The next day, cells were transfected using the Ef-
fectene kit (QIAGEN). Per transfection, 50 ng of the IFN-  reporter plasmid
pGL3-mIFN 564-Luc, 2 ng of the Renilla luciferase control vector pRL-
TK (Promega), and 50 or 200 ng of the expression vectors encoding T-bet or
Ets-1, respectively, or empty control vectors were used. 1 d after transfection,
the cells were harvested and the cell lysates were assayed for luciferase activity
using the Dual Luciferase Reporter System (Promega) according to the man-
ufacturer’s instructions. The IFN-  reporter pGL3-mIFN 564-Luc, a gift
from M. Townsend (Harvard School of Public Health, Boston, MA) and L.
Glimcher, contains 564 bp upstream of the mouse IFN-  transcriptional start
site and 112 bp downstream up to the ATG. The Ets-1 expression vector
pcDNA3 Flag-Ets1 was constructed by inserting a full-length murine Ets-1
cDNA into the BamHI site of pcDNA3 Flag (provided by J. Leiden, Abbott
Laboratories, Chicago, IL), resulting in an NH2 terminally FLAG-tagged Ets-1
product. The T-bet expression vector pcDNAHis-Tbet was a gift from L.
Glimcher and was described previously (7). Site-specific mutagenesis of po-
tential Ets binding sites was performed using the QuikChange XL kit (Strata-
gene) following the manufacturers instructions. The core Ets binding motif
(GGAA) was altered to a restriction site (GGAAGC to GCTAGC for EBS
and AGGAAA to AGTACT for ISRE). MatInspector software was used to
ensure that the mutation did not create a new potential transcription factor
binding site. The following primers were used for mutagenesis: EBS, 5 -
CGATCAGGTATAAAACTGCTAGCCAGAGAGGTGCAGGC-3  and
5 -GCCTGCACCTCTCTGGCTAGCAGTTTTATACCTGATCG-3 .
For the ISRE: 5 -GAGAGCCCAAGGAGTCGAAAGTACTCTCTAA-
CATGCCACAAAACC-3  and 5 -GGTTTTGTGGCATGTTAGAGAG-
TACTTTCGACTCCTTGGGCTCTC-3 .
ChIP. ChIP was essentially performed as described previously (26) except
that Staph A cells were replaced with protein A–sepharose. A detailed proto-
col is available upon request. The following antibodies were used for precipi-
tation: rabbit anti–Ets-1 (C-20; Santa Cruz Biotechnology, Inc.), rabbit anti–
T-bet (a gift from L. Glimcher). To amplify the IFN-  promoter region and
the Ets-1 intron 2/exon 3, we used the following primer pairs, respectively:
5 -GTCGAAAGGAAACTCTAACATGCC-3  and 5 -ATCAGCTGAT-
GTGTCTTCTCTAGG-3 , and 5 -GAGGAGATCAATGGAAATCTTG-
GCC-3  and 5 -GATATCCCCAACAAAGTCTGGAGC-3 .
Western blot analysis. Nuclear extracts or total cell lysates were adjusted
for total protein concentration and subjected to SDS-PAGE and Western
blot. The following antibodies were used: anti–Ets-1 (N-276; Santa Cruz
Biotechnology, Inc.), anti–T-bet, anti–phospho-STAT4 (ST4P; Zymed
Laboratories), anti-STAT4 (C-20; Santa Cruz Biotechnology, Inc.), anti–
phospho-STAT1 (Tyr701; Cell Signaling Technology), anti-STAT1 (E-23;
Santa Cruz Biotechnology, Inc.), and anti-Hsp90 (H-114; Santa Cruz Bio-
technology, Inc.). All primary antibodies are rabbit polyclonals except for
the goat antiactin (I-19; Santa Cruz Biotechnology, Inc.). As secondary an-
tibodies, HRP-coupled goat anti–rabbit IgG or rabbit anti–goat IgG
(Zymed Laboratories) were used. Proteins were visualized using an ECL
Western Lightning kit (PerkinElmer).
Real-time PCR. Total RNA was isolated using TRIzol and treated with
DNaseI. The RNA was reverse transcribed using the Superscript II RT kit
(Invitrogen). Control reactions without RT were also used to ensure that no
genomic DNA was detected. All PCR reactions were done in triplicate on an
ABI Prism 7700 Sequence Detector (Applied Biosystems). IL-12R 2 was am-
plified using SYBR green PCR master mix and  -actin was amplified using
Taqman Universal PCR master mix (Applied Biosystems). Relative mRNA
amounts were calculated by the expression 2 (CTsample   CTactin) where CT is the
threshold cycle. The following primers and probes were used: IL-12R 2
sense, 5 -CCCAAGGAAATGAAAGGGAATT-3  and antisense: 5 -TAGC-
GATGCAAATGCTTGATATC-3 ;  -actin, FAM probe, 5 -TCAAGAT-
CATTGCTCCTCCTGAGCGC-3 , sense, 5 -GCTCTGGCTCCTAGCA-
CCAT-3  and antisense, 5 -GCCACCGATCCACACCGCGT-3 .
Online supplemental material. Fig. S1 shows the purity of differentiated
Th cells. Fig. S2 depicts the kinetics of STAT4 and IL-12R 2 expression
upon primary stimulation. Fig. S3 demonstrates that early addition of exoge-
nous IL-2 does not rescue the defective cytokine production by Ets-1    Th
cells. Fig. S4 shows that exogenous IFN-  does not inhibit the overproduc-
tion of IL-10 by Ets-1    Th cells. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20041330/DC1.
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